@article{6d590caa6a714d79a2bbd17122780870,
title = "A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial",
keywords = "clinical trial, complete hematologic response, essential thrombocythemia (ET), higher initial dose and accelerated titration (HDAC) regimen, molecular response, ropeginterferon alfa-2b-njft (ropeg)",
author = "Lucia Masarova and Reeves, \{Brandi N.\} and \{El Chaer\}, Firas and Lynda Foltz and Tsewang Tashi and Ghaith Abu-Zeinah and Jennifer Lucas and Halpern, \{Anna B.\} and Dawn Maze and Albert Qin and Hana Safah and Fengshuo Lan and O'Connell, \{Casey L.\} and Swati Goel and Lindsay Rein and Bruno Fang and Joan How and Sunil Babu and Zhuoyan Li and Sonia Cerquozzi and Oh, \{Stephen T.\} and Hunter, \{Anthony M.\} and Nikolai Podoltsev and Pankit Vachhani and Abdulraheem Yacoub and Cunningham, \{Julia M.\} and Christopher Hillis and Salman Otoukesh and Oleh Zagrijtschuk and Henry Castro and Prithviraj Bose",
year = "2025",
doi = "10.3389/fmed.2025.1548590",
language = "English",
volume = "12",
journal = "Frontiers in Medicine",
issn = "2296-858X",
}